Genetic Strategies: Knockout Validated: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and LAMP2 knockout (KO) HeLa cell line. PVDF membrane ...read more
Immunocytochemistry/ Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Immunofluorescence: [Alexa Fluor® 647] [NBP2-22217AF647] - T98G glioblastoma cells grown on #1.5 coverglass stained with a ...read more
Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Analysis of LAMP-2/CD107b expression in Whole Cell Lysates: 2) HeLa, 3) Jurkat, 4) U937, 5) HepG2, Tissue Extracts: 6) Human kidney, 7) Human lung, 8) Human ...read more
Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Staining of LAMP-2/CD107b in human liver using DAB with hematoxylin counterstain.
Simple Western: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lane view shows a specific band for LAMP-2/CD107b in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa ...read more
Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - An intracellular stain was performed on U937 cells with HGF LAMP-2/CD107b [H4B4] Antibody NBP2-22217AF647 (blue) and a matched isotype control (orange). Cells ...read more
Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Localization of TMEM135 to the mitochondria. The mitochondrial fraction isolated from the WT mouse brain show TMEM135 signals by immunoblotting. Following ...read more
Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Representative pictures of effect of I/R on DNA damage, cell survival, and inflammation. Western blot analysis expression level of Cathepsin B (*P < 0.05) in ...read more
Immunocytochemistry/ Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The ...read more
Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Intracellular flow cytometric staining of 1 x 10^6 HEK-293 cells using anti-LAMP-2/CD107b (dark blue). Isotype control shown in orange. An antibody ...read more
ELISA: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Anti-LAMP-2/CD107b was used to assess lysates from human SVG-A cells via ELISA, by loading the indicated mass of total protein per well. Antibodies tested were diluted ...read more
LAMP-2/CD107b Antibody (H4B4) was made using a human adherent spleen cells.
Cell membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note: This protein shuttles between lysosomes, endosomes, and the plasma membrane.
Late Endosome / Lysosome marker
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
In Western blot, bands may be seen at ~40 kDa and 45 kDa representing the unglycosylated isoforms of LAMP2 and ~110 kDa representing the glycosylated form.
In Simple Western only 10 - 15 ul of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue. This antibody is CyTOF ready. Use in immunoblotting reported in scientific literature (PMID: 29643474).
45 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Mouse reactivity reported in scientific literature (PMID: 27863209). Chicken reactivity reported in scientific literature (PMID: 30298003).
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.05% Sodium Azide
Protein G purified
Alternate Names for LAMP-2/CD107b Antibody (H4B4)
CD107 antigen-like family member B
Lysosomal Associated Membrane Protein 2
lysosomal-associated membrane protein 2
lysosome-associated membrane glycoprotein 2
Lysosome-associated membrane protein 2
LAMP-2 (Lysosome-associated membrane protein 2) is a single-pass type I membrane protein that belongs to a family of membrane glycoproteins (~40 KDa). LAMP-2 protein is encoded by nine exons, with the first 8 exons and a portion of exon 9 encoding the highly glycosylated protein domains within the lysosomal lumen. The transmembrane and cytosolic carboxy-terminal domains of LAMP-2 are encoded by the remaining sequence of exon 9 and conform the receptor for targeting proteins to the lysosome. Splicing of exon 9 in the LAMP-2 pre mRNA leads to various splice forms with distinct cytosolic domains. Three splice variants, LAMP-2A, -2B and -2C, have been identified which shuttle between the plasma membrane, endosomal compartment and lysosomes (1). Tissue specific expression has been described for each LAMP-2 splice variant, with LAMP-2A being more ubiquitously expressed (e.g., placenta, lung, liver, pancreas and prostate), LAMP-2B predominantly expressed in skeletal muscle and LAMP-2C in brain tissue (1). All LAMP-2 splice variants participate in lysosomal degradation processes. LAMP-2A is the only variant that serves as a receptor targeting proteins for lysosomal degradation in chaperone-mediated autophagy (2,3). LAMP-2B is essential for macroautophagy in cardiomyocytes, where it facilitates autophagosome-lysosome fusion. LAMP-2B mutations underscore the myopathy and severe hypertrophic cardiomyopathy in Danon disease which results from deficits in autophagy (1, 4). Vasculopathy of coronary and cerebral arteries is a rare phenotype in Danon patients that is also associated with deficient autophagy processing of proteins and cellular organelles (5). LAMP2C serves as a receptor for DNA and RNA, facilitating their lysosomal degradation through DNA-autophagy and RNA-autophagy, respectively (1).
1. Rowland, T. J., Sweet, M. E., Mestroni, L., & Taylor, M. R. G. (2016). Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. Journal of Cell Science. https://doi.org/10.1242/jcs.184770
2. Alfaro, I. E., Albornoz, A., Molina, A., Moreno, J., Cordero, K., Criollo, A., & Budini, M. (2019). Chaperone mediated autophagy in the crosstalk of neurodegenerative diseases and metabolic disorders. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2018.00778
3. Schneider, J. L., & Cuervo, A. M. (2014). Autophagy and human disease: Emerging themes. Current Opinion in Genetics and Development. https://doi.org/10.1016/j.gde.2014.04.003
4. Chi, C., Leonard, A., Knight, W. E., Beussman, K. M., Zhao, Y., Cao, Y., Song, K. (2019). LAMP-2B regulates human cardiomyocyte function by mediating autophagosome lysosome fusion. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.1808618116
5. Nguyen, H. T., Noguchi, S., Sugie, K., Matsuo, Y., Nguyen, C. T. H., Koito, H., Tsukaguchi, H. (2018). Small-Vessel Vasculopathy Due to Aberrant Autophagy in LAMP-2 Deficiency. Scientific Reports. https://doi.org/10.1038/s41598-018-21602-8
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.